News
Video
Generics and Biosimilars in Multiple Sclerosis
Key opinion leaders explore the impact of newly available biosimilars and generic biologics for managing multiple sclerosis (MS), discussing how these developments have altered patient access to treatments and the implications for the future of the MS treatment landscape.
Video Player is loading.
- Generics or biosimilar versions of many MS treatments are now available.
- How has this changed access to MS treatment for patients?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Videos
Final Thoughts on Caring for Patients With Mild/Moderate Multiple Sclerosis
Emerging Treatments in Mild/Moderate Multiple Sclerosis
Diagnostic Uncertainty, Monitoring and Other Unmet Needs in Mild/Moderate Multiple Sclerosis
Benign Multiple Sclerosis
Treatment Adherence in Mild Multiple Sclerosis
Choosing Between Moderate Therapies for Mild/Moderate Multiple Sclerosis
De-Escalation Strategies and Challenges With the Use of HET in Mild/Moderate Multiple Sclerosis
Shared Decision-Making for Patients With Mild/Moderate Multiple sclerosis
Monitoring Patients With Mild/Moderate Multiple Sclerosis
Conversations With Patients About Mild/Moderate Multiple Sclerosis
Related Content
